Learn how the benefits of GLP-1s may be outweighed by the risks.

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

An Ozempic-like drug prescribed for diabetes has been found to reduce the frequency of debilitating migraine. Researchers say ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence individuals' weight loss after taking ...

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced ...

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

Most individuals with chronic kidney disease (CKD) are unaware of their disease, according to a KDIGO controversies conference on CKD prevention.

The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

Hims & Hers is pitching consumers on a GLP-1 weight loss injection that will cost 85% less than brand-name drugs like Wegovy.

A new study has suggested the benefits of GLP-1 agonists could extend to a reduction in the risk of a slew of cancers associated with being overweight. The observational study of more than 170,000 ...